![Johan Dighed](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Johan Dighed
Direttore/Membro del Consiglio presso PROMIMIC AB
Profilo
Johan Dighed is currently the Chief Legal Officer & Deputy CEO at Karolinska Development AB.
He is also a Director at Promimic AB, KCIF Fund Management AB, KDev Oncology AB, Modus Therapeutics AB, KD Incentive AB, KDev Investments AB, and AnaCardio AB.
Previously, he worked as the Head-Legal at DSK Hyp AG.
Mr. Dighed graduated from the University of Lund.
Posizioni attive di Johan Dighed
Società | Posizione | Inizio |
---|---|---|
KAROLINSKA DEVELOPMENT AB | Consigliere Generale | 01/05/2020 |
PROMIMIC AB | Direttore/Membro del Consiglio | 01/01/2021 |
AnaCardio AB
![]() AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Direttore/Membro del Consiglio | - |
KDev Oncology AB
![]() KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | - |
KDev Investments AB
![]() KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | - |
KCIF Fund Management AB | Direttore/Membro del Consiglio | - |
KD Incentive AB | Direttore/Membro del Consiglio | - |
Modus Therapeutics AB
![]() Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Johan Dighed
Società | Posizione | Fine |
---|---|---|
DSK Hyp AG
![]() DSK Hyp AG Major BanksFinance DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany. | Consigliere Generale | - |
Formazione di Johan Dighed
University of Lund | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
KAROLINSKA DEVELOPMENT AB | Finance |
PROMIMIC AB | Health Technology |
Aziende private | 7 |
---|---|
DSK Hyp AG
![]() DSK Hyp AG Major BanksFinance DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany. | Finance |
AnaCardio AB
![]() AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |
KDev Oncology AB
![]() KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Commercial Services |
KDev Investments AB
![]() KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Health Technology |
KCIF Fund Management AB | |
KD Incentive AB | |
Modus Therapeutics AB
![]() Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Johan Dighed